PFE - Cancer Treatment Focused Immuneering Faces Analyst Downgrades Who Cite Underwhelming Solid Tumor Trial Data | Benzinga
Thursday, Immuneering Corporation (NASDAQ:IMRX) revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors.
Friday, shares are trading lower after several analysts downgraded the stock after the company released the data.
Needham writes that IMM-1-104’s Phase 1b data validated its mechanism of action at the safety, PK/PD, and ctDNA level, but it did not translate into partial response (PR)/ complete response (CR), which raises concerns about its efficacy as a monotherapy.
Needham notes that the lack of positive or complete response in clinical trials may stem from various reasons, such as small sample sizes, a significant proportion of patients with advanced disease, and the majority not ...